Phase I study with an autologous tumor cell vaccine for locally advanced or metastatic prostate cancer

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 10, Issue 2, 2007, Pages 144-151

  Berger, Milton ^a,d   Kreutz, Fernando T ^b,c   Horst, Jorge L ^a   Baldi, Aline C ^c   Koff, Walter J ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c FK Biotecnologia SA   (Brazil)

^d NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; PROSTATE SPECIFIC ANTIGEN; TUMOR CELL VACCINE;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE SCINTISCANNING; CANCER CELL CULTURE; CANCER STAGING; CELL ISOLATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; DELAYED HYPERSENSITIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ERYTHEMA; FOLLOW UP; HUMAN; INCUBATION TIME; INJECTION SITE INDURATION; INOCULATION; IRRADIATION; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PROSTATE CANCER; PRURITUS; RADICAL RETROPUBIC PROSTATECTOMY; TRANSURETHRAL RESECTION; ULCER; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; BCG VACCINE; CANCER VACCINES; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY, ACTIVE; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 34249304821     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. INCA (Instituto Nacional do Câncer). Available at http://inca.gov.br/ (accessed mars 2005)
2. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A. et al: Cancer Statistics, 2005. CA Cancer J Clin, 55: 10, 2005
3. Kupelian, P. A., Potters, L., Khuntia, D., Ciezki, J. P., Reddy, C. A., Reuther, A. M. et al: Radical prostatectomy, external beam radiotherapy < 72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys, 58: 25, 2004
4. Khan, M. A., Partin, A. W.: Management of high-risk populations with locally advanced prostate cancer. Oncologist, 8: 259, 2003
5. Cho, D., Di Blasio, C. J., Rhee, A. C., Kattan, M. W.: Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT). Urol Oncol, 21: 282, 2003
6. Pantuck, A. J., Zisman, A., Henderson, D., Wilson, D., Schreiber, A., Belldegrun, A.: New biologicals for prostate cancer prevention: genes, vaccines, and immune-based interventions. Urology, 57 Suppl: 95, 2001
7. Ward, S., Casey, D., Labarthe, M. C., Whelan, M., Dalgleish, A., Pandha, H. et al.: Immunotherapeutic potential of whole tumour cells. Cancer Immunol Immunother, 51: 351, 2002
8. Rosenberg, S. A.: Development of effective immunotherapy for the treatment of patients with cancer. J Am Coll Surg, 198: 685, 2004
9. Berzofsky, J. A., Terabe, M., Oh, S., Belyakov, I. M., Ahlers, J. D., Janik, J. E., Morris, J. C.: Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest, 113: 1515, 2004
10. Smyth, M. J., Godfrey, D. I., Trapani, J. A.: A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol, 2: 293, 2001
11. Mocellin, S., Mandruzzato, S., Bronte, V., Lise, M., Nitti, D.: Part I: vaccines for solid tumors. Lancet Oncol, 5: 681, 2004
12. Blades, R. A., Keating, P. J., McWilliam, L. J., George, N. J., Stern, P. L.: Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology, 46: 681, 1995
13. Belardelli, F., Ferrantini, M., Proietti, E., Kirkwood, J. M.: Interpheron-alpha in tumor immunity and immunology. Cytokine Growth Factor Rev, 13: 119, 2002
14. Li, Q., Normolle, D. P., Sayre, D. M., Zeng, X., Sun, R., Jiang, G. et al.: Immunological effects of BCG as an adjuvant in autologous tumor vaccines. Clin Immunol, 94:64,2000
15. Morales, A., Eidinger, D., Bruce, A.W.: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumours. J Urol, 116: 180, 1976
16. Bohle, A., Brandau S.: Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol, 170: 964, 2003
17. von Meyenn, F., Schaefer, M., Weighardt, H., Bauer, S., Kirschning, C.J., Wagner, H., Sparwasser, T.: Toll-like receptor 9 contributes to recognition of Mycobacterium bovis Bacillus Calmette-Guerin by Flt3-ligand generated dendritic cells. Immunobiology, 211: 557,2006
18. Akira, S., Takeda, K.: Toll-like receptor signalling. Nat Rev Inimunol, 7: 499, 2004.
19. Simons, J. W., Mikhak, B., Chang, J. F., DeMarzo, A. M., Carducci, M. A., Lim, M. et al.: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res, 59: 5160, 1999
20. Vermorken, J. B., Claessen, A. M., van Tinteren, H., Gall, H. E., Ezinga, R., Meijer, S. et al.: Active specific immunotherapy for stage II and,III human colon cancer: a randomised trial. Lancet, 353: 345, 1999
21. Nelson, W. G., Simons, J. W., Mikhak, B., Chang, J. F., DeMarzo, A. M., Carducci, M. A. et al.: Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemoter Pharmacol, 46 Suppl: S67, 2000
22. Clay, T. M., Hobeika, A. C., Mosca, P. J., Lyerly, H. K., Morse, M. A.: Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res, 7: 1127, 2001
23. Disis, M. L., Schiffman, K., Gooley, T. A., McNeel, D. G., Rinn, K., Knutson, K. L.: Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res, 6: 1347, 2000
24. Eaton, J. D., Perry, M. J., Nicholson, S., Guckian, M., Russell, N., Whelan, M. et al.: Allogeneic whole-cell vaccine: a phase I/Il study in men with hormone-refractory prostate cancer. BJU Int, 89: 19, 2002